Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome

[PR Newswire] – THOUSAND OAKS, Calif. and HOUSTON, Jan. 12, 2015 /PRNewswire/ — Amgen (AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen’s . . . → Read More: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome Similar Articles: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Kite Pharma ink deal to develop cancer immunotherapies Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival